Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer’s disease

What is it about?

There has yet been a reliable method to objectively monitor the biological progression of Alzheimer's disease. We show that neuronal pentraxin receptor (NPTXR) in the cerebrospinal fluid could indicate patient severity of Alzheimer's disease, and may serve as a useful biomarker for the clinic.

Featured Image